Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

This study has been terminated.
(Difficulty in patient recruitment in the participating sites)
Information provided by (Responsible Party):
Sanofi Identifier:
First received: July 6, 2011
Last updated: November 25, 2014
Last verified: November 2014

Primary Objective:

- To determine the pharmacokinetics (PK) of a single intravenous (IV) dose of SAR279356 administered to intensive care unit (ICU) patients on mechanical ventilation

Secondary Objectives:

  • To determine the safety and tolerability of SAR279356
  • To evaluate the pharmacodynamics (PD) and immunogenicity of SAR279356
  • Exploratory efficacy of SAR279356 on prevention of bacterial infections

Condition Intervention Phase
Infection Prophylaxis
Drug: SAR279356
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Pharmacokinetics parameters of SAR279356 : Ceoi, AUClast and CL [ Time Frame: 90 days ]

Secondary Outcome Measures:
  • Opsonophagocytic assay (OPA) [ Time Frame: 90 days ]
  • Opsonophagocytic killing assay (OPK) [ Time Frame: 90 days ]
  • Dosage of human anti-human antibodies (HAHA) [ Time Frame: 90 days ]
  • Occurrence of infections [ Time Frame: Up to 28 days ]

Enrollment: 7
Study Start Date: October 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SAR279356 dose 1
SAR279356 dose 1, single administration
Drug: SAR279356

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Experimental: SAR279356 dose 2
SAR279356 dose 2, single administration
Drug: SAR279356

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Placebo Comparator: Placebo
Matching placebo, single administration
Drug: placebo

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Detailed Description:

Total study duration (from screening to last follow-up visit) is 91 days break down as follows:

  • Screening: 1 day prior to dosing;
  • Treatment period: one IV injection on Day 1;
  • Follow-up period: 90 days

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria :

  • ICU patients on mechanical ventilation at the time of randomization
  • Patients or legally authorized representative (LAR) giving written informed consent.

Exclusion criteria:

  • Patients <18 years of age;
  • Documented Pseudomonas infection or colonization in the last 30 days;
  • Immunocompromised patients
  • Hypersensitivity to the study drug and/or to prior therapy with monoclonal antibodies;
  • Patient who has taken other investigational drugs or prohibited therapy for this study within 1 month or 5 half-lives, whichever is longer;
  • Patient or LAR who withdraws consent during the screening (starting from signed informed consent form);
  • Acute liver injury related criteria at the time of study entry:
  • Pregnant or breast-feeding women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01389700

United States, California
Investigational Site Number 840010
Los Angeles, California, United States, 90024
Investigational Site Number 840020
Stanford, California, United States, 94305
United States, Florida
Investigational Site Number 840006
Jacksonville, Florida, United States, 32209
United States, Kentucky
Investigational Site Number 840001
Pikeville, Kentucky, United States, 41501
United States, Montana
Investigational Site Number 840009
Butte, Montana, United States, 59701
United States, New Jersey
Investigational Site Number 840003
Camden, New Jersey, United States, 08103
Sponsors and Collaborators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT01389700     History of Changes
Other Study ID Numbers: PKD11791
U1111-1118-6717 ( Other Identifier: UTN )
Study First Received: July 6, 2011
Last Updated: November 25, 2014 processed this record on May 23, 2017